Health and Business, or Vice Versa
It’s potentially the greatest opportunity ever presented to the world of business. Coincidentally it’s also the greatest opportunity for massive fraud. It’s the elusive Covid-19 vaccine. One wonders what is going through the heads of the pharmaceutical executives competing for the biggest prize ever, a vaccine that every person in the world urgently needs, and for which the producers can virtually name their own price, just as they do with the medicines they sell to the American Social Security administration.
It also presents the greatest opportunity to save lives, reactivate economies, and bring the world back to life. But, given the American pharmaceutical industry’s track record, one suspects that the economic incentive is their first priority. Let’s take a look at how they’re doing thus far.
Operation Warp Speed, the Trump Administration’s Six-Billion-Dollar Vaccine Betting Shop
As of early July this program of massive Trump administration cash handouts extends to eight pharmaceutical companies for expediting development and preparation for the clinical trials necessary for the manufacturing of their respective vaccine candidates: Johnson & Johnson (Janssen Pharmaceutical), AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Merck, Vaxart, Inovio, and Novavax. According to Science magazine, Francis Collins, Director of the National Institutes of Health (NIH), said a group of vaccine experts his agency convened to work with Warp Speed did a scientific review of 50 candidate COVID-19 vaccines. Members of that group have expressed surprise at some of Warp Speed’s choices. Continue reading “The Race Is on for Coronavirus Vaccine Profits”